Immix Biopharma (NASDAQ:IMMX – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09, Zacks reports.
Immix Biopharma Trading Down 1.1 %
Immix Biopharma stock traded down $0.02 during midday trading on Wednesday, hitting $1.83. The stock had a trading volume of 12,323 shares, compared to its average volume of 133,311. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $3.23. The company has a market capitalization of $50.34 million, a PE ratio of -2.15 and a beta of 0.26. The firm’s fifty day moving average is $1.86 and its two-hundred day moving average is $1.86.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a report on Monday, February 10th.
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
See Also
- Five stocks we like better than Immix Biopharma
- Stock Average Calculator
- Energy Transfer: Powering Data With Dividends and Diversification
- Are Penny Stocks a Good Fit for Your Portfolio?
- Qualcomm Stock Is Coiling for a Breakout
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
